Are you over 18 and want to see adult content?
More Annotations
![A complete backup of www.shieldsgazette.com/sport/football/newcastle-united/marginally-better-absolute-lack-quality-liam-kennedy](https://www.archivebay.com/archive2/f812e86b-8272-444c-8d4d-e4a4d01cb147.png)
A complete backup of www.shieldsgazette.com/sport/football/newcastle-united/marginally-better-absolute-lack-quality-liam-kennedy
Are you over 18 and want to see adult content?
![A complete backup of www.gqindia.com/entertainment/content/in-w-vs-sl-w-womens-t20-world-cup-dream11-prediction-match-top-picks-](https://www.archivebay.com/archive2/4eb9b9f6-b4c8-4c43-b9db-5a16d6656029.png)
A complete backup of www.gqindia.com/entertainment/content/in-w-vs-sl-w-womens-t20-world-cup-dream11-prediction-match-top-picks-
Are you over 18 and want to see adult content?
Favourite Annotations
![Career Authors • Write. Sell. Repeat.](https://www.archivebay.com/archive/2f1d3608-026c-4d68-ae7d-82672b7a9e67.png)
Career Authors • Write. Sell. Repeat.
Are you over 18 and want to see adult content?
![Party.pl Newsy, zdjęcia, filmy. O gwiazdach wiemy wszystko! | Party.pl](https://www.archivebay.com/archive/93b6ff64-3039-47cd-a17a-1f2a4c149676.png)
Party.pl Newsy, zdjęcia, filmy. O gwiazdach wiemy wszystko! | Party.pl
Are you over 18 and want to see adult content?
![Seby Augustine | A self-taught artist and graphic designer](https://www.archivebay.com/archive/b086afe8-81b3-423a-9093-733174644725.png)
Seby Augustine | A self-taught artist and graphic designer
Are you over 18 and want to see adult content?
![WinSysBlog - Windows. PowerShell. Life.](https://www.archivebay.com/archive/ed6e533f-331e-4880-a1af-673e283d5f5e.png)
WinSysBlog - Windows. PowerShell. Life.
Are you over 18 and want to see adult content?
![FastFormat - Formatação automática nas normas ABNT, APA, Vancouver e outras.](https://www.archivebay.com/archive/764c643d-87a8-4d51-b533-9946b0c1a839.png)
FastFormat - Formatação automática nas normas ABNT, APA, Vancouver e outras.
Are you over 18 and want to see adult content?
![Torrent Oyun indir, Full, PC Kaliteli, hizli ve reklamsiz](https://www.archivebay.com/archive/6ca1c133-d1af-44b3-a5d7-5b262b3c4cce.png)
Torrent Oyun indir, Full, PC Kaliteli, hizli ve reklamsiz
Are you over 18 and want to see adult content?
Text
dinner offers.
BIA | CHARITY OF THE YEAR 2022 APPLICATION FORM Yes. No. Are you properly constituted and compliant with all areas of charity law (for example, filing of proper accounts on time) Yes. No. Are you/will you become a member of the Association of Medical Research (AMRC) Yes. No. How much you have spent on biomedical research in the UK in the last three years (% of overallincome/wealth)
BIA | LIFE SCIENCES 2030 SKILLS STRATEGY The UK BioIndustry Association (BIA) has welcomed today’s publication of the Life Sciences 2030 Skills Strategy . The report is a key deliverable from the Life Sciences Sector Deal 2 and sets out how the UK Life Sciences sector will attract, retain, train and develop the research, manufacturing and technical skills required by a dynamic and diverse UK sector. BIA | RARE DISEASE INDUSTRY GROUP The BIA Rare Disease Industry Group (RDIG) represents a group of innovative bioscience companies that specialise in treatments for rare and ultra-rare diseases. The RDIG is committed to developing recommendations that can pragmatically inform and improve the challenge of ensuring patient access to treatments for rare and ultra-rare conditions BIA | AUSPHERIX LIMITED Auspherix Limited. Auspherix is an early-stage anti-infectives company offering new hope in the battle against antibiotic resistant bacteria. By developing a new class of antibiotics the Company will strengthen the existing arsenal of antibacterial treatments. Auspherix’ pre-clinical R&D programmes are based on its discovery ofantibacterials
GUIDANCE: FREQUENTLY ASKED QUESTIONS Page 3 of 24 8. Section 15 of the CAP conversion guidance clarifies some of the requirements for the UK MAH following the UK’s exit from the EU.However, the requirements to submit texts orBIA | GLYCOVUE LTD
GlycoVue Ltd. GlycoVue is a spin-off from the University of Cambridge and represents the accumulation of more than 15 years of experimental research in near-continuous glucose monitoring in readily accessible biological fluids. GlycoVue combines glucose-responsive smart polymers with advanced holography and AI-enabled smartphone-based BIA | CELL MEDICA LTD Cell Medica Ltd. Cell Medica is developing transformative new treatments for cancer based genetically engineering the patient’s immune cells to recognize and kill and malignant cells. Our strategy targets solid tumors and includes both autologous and allogeneic (off-the-shelf) cell therapies incorporating chimeric antigen receptors (CARs) and CELL AND GENE THERAPY EXPLAINED A GUIDE TO CELL AND GENE CAR-T cell-based medicines include both a gene therapy element (the new receptor molecule) and a cell therapy element (the cells injected back into the patient). VACCINE MANUFACTURING TASKFORCE KEY MESSAGES Influence, connect, save www.bioindustry.org 1,000,000 from 200L of cell culture, which is not uncommon. The ambition is a realistic oneand
BIA | GARDEN PARTY 2021 #BIAGardenParty. Since we will be able to meet in person again from the summer, we have decided to throw a garden party! This will give the community the chance to finally meet face to face and make up for the missed networking opportunities that our traditional January Galadinner offers.
BIA | CHARITY OF THE YEAR 2022 APPLICATION FORM Yes. No. Are you properly constituted and compliant with all areas of charity law (for example, filing of proper accounts on time) Yes. No. Are you/will you become a member of the Association of Medical Research (AMRC) Yes. No. How much you have spent on biomedical research in the UK in the last three years (% of overallincome/wealth)
BIA | LIFE SCIENCES 2030 SKILLS STRATEGY The UK BioIndustry Association (BIA) has welcomed today’s publication of the Life Sciences 2030 Skills Strategy . The report is a key deliverable from the Life Sciences Sector Deal 2 and sets out how the UK Life Sciences sector will attract, retain, train and develop the research, manufacturing and technical skills required by a dynamic and diverse UK sector. BIA | RARE DISEASE INDUSTRY GROUP The BIA Rare Disease Industry Group (RDIG) represents a group of innovative bioscience companies that specialise in treatments for rare and ultra-rare diseases. The RDIG is committed to developing recommendations that can pragmatically inform and improve the challenge of ensuring patient access to treatments for rare and ultra-rare conditions BIA | AUSPHERIX LIMITED Auspherix Limited. Auspherix is an early-stage anti-infectives company offering new hope in the battle against antibiotic resistant bacteria. By developing a new class of antibiotics the Company will strengthen the existing arsenal of antibacterial treatments. Auspherix’ pre-clinical R&D programmes are based on its discovery ofantibacterials
GUIDANCE: FREQUENTLY ASKED QUESTIONS Page 3 of 24 8. Section 15 of the CAP conversion guidance clarifies some of the requirements for the UK MAH following the UK’s exit from the EU.However, the requirements to submit texts orBIA | GLYCOVUE LTD
GlycoVue Ltd. GlycoVue is a spin-off from the University of Cambridge and represents the accumulation of more than 15 years of experimental research in near-continuous glucose monitoring in readily accessible biological fluids. GlycoVue combines glucose-responsive smart polymers with advanced holography and AI-enabled smartphone-based BIA | CELL MEDICA LTD Cell Medica Ltd. Cell Medica is developing transformative new treatments for cancer based genetically engineering the patient’s immune cells to recognize and kill and malignant cells. Our strategy targets solid tumors and includes both autologous and allogeneic (off-the-shelf) cell therapies incorporating chimeric antigen receptors (CARs) and CELL AND GENE THERAPY EXPLAINED A GUIDE TO CELL AND GENE CAR-T cell-based medicines include both a gene therapy element (the new receptor molecule) and a cell therapy element (the cells injected back into the patient). VACCINE MANUFACTURING TASKFORCE KEY MESSAGES Influence, connect, save www.bioindustry.org 1,000,000 from 200L of cell culture, which is not uncommon. The ambition is a realistic oneand
BIA | BIA START-UP FESTIVAL The BIA are delighted to announce a new event for emerging companies, the BIA Start-up Festival, which will take place in virtual format this May. This event will bring together the best of rising talent in the sector for a day of networking, 1-1 meetings, and educational sessions designed to build on your existing knowledge and allow you to BIA | MMIP VIRTUAL CONFERENCE We’re delighted to announce the annual MMIP conference, to be held virtually on Wednesday 16 June, 13.00 to 17.00. The pandemic has highlighted the importance of global medicines supply chains, and generated unprecedented discussion around the manufacturing of medicines and vaccines; there has even been public discussion in the media about the challenges of manufacturing scale up and batch BIA | CHARITY OF THE YEAR 2022 APPLICATION FORM Yes. No. Are you properly constituted and compliant with all areas of charity law (for example, filing of proper accounts on time) Yes. No. Are you/will you become a member of the Association of Medical Research (AMRC) Yes. No. How much you have spent on biomedical research in the UK in the last three years (% of overallincome/wealth)
BIA | LIFE SCIENCES 2030 SKILLS STRATEGY The UK BioIndustry Association (BIA) has welcomed today’s publication of the Life Sciences 2030 Skills Strategy . The report is a key deliverable from the Life Sciences Sector Deal 2 and sets out how the UK Life Sciences sector will attract, retain, train and develop the research, manufacturing and technical skills required by a dynamic and diverse UK sector. BIA | VISUSNANO OPENS NEW FACILITY AT DISCOVERY PARK AND Sandwich, Kent, 17th September 2020 Medtech company VisusNano announces the opening of its 800 sq. ft facility at Discovery Park, the Life Sciences Opportunity Zone for ambitious and growingcompanies.
BIA | IKSUDA THERAPEUTICS CLOSES $47 MILLION FINANCING ROUND Newcastle, UK, 7 June 2021: Iksuda Therapeutics (Iksuda), the developer of a new generation of antibody drug conjugates (ADCs) with raised therapeutic index, today announced it has completed a US $47 million (circa GB £34 million) financing round, co-led by Mirae Asset Capital and its subsidiaries, Celltrion and Premier Partners, with the Company being advised by Ashfords LLP. BIA | GENOMICS ADVISORY COMMITTEE (GAC) The BIA’s Genomics Advisory Committee (GAC) ensures that the UK starts, scales and builds world leading genomic businesses. The Committee acts as a leadership platform for sharing and discussing issues of common concern between genomic businesses and provides expert advice to the BIA to collectively input to relevant policy discussions, especially with the UK government. BIA | ARECOR APPOINTS DR. LINDSEY FOULKES AS CHIEF Arecor Therapeutics plc (“Arecor”, the “Company” or the “Group”) ARECOR APPOINTS DR. LINDSEY FOULKES AS CHIEF OPERATING OFFICER Cambridge, UK, 10 June 2021: Arecor Therapeutics plc (AIM: AREC), a globally focused biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces the appointment of Dr. Lindsey Foulkes as the Company’s Chief BIA | WHP COMPLETES THE MANUFACTURE OF THEIR LARGEST Multi-disciplinary engineering company WHP were awarded the contract to design and build a fully modularised containment facility. The project comprised the design and manufacture of 122 cGMP modules, making it one of the largest modular cGMP facilities in Europe. BIA | WHP COMPLETES NEW CLEANROOM AND PRODUCTION New state of the art cleanroom and production facilities for a leading UK MHRA approved and NHS Accredited Specials Manufacturing Company will assist them in their goal of becoming a centre of medical cannabis excellence for the UK. BIA | GARDEN PARTY 2021 #BIAGardenParty. Since we will be able to meet in person again from the summer, we have decided to throw a garden party! This will give the community the chance to finally meet face to face and make up for the missed networking opportunities that our traditional January Galadinner offers.
BIA | CHARITY OF THE YEAR 2022 APPLICATION FORM Yes. No. Are you properly constituted and compliant with all areas of charity law (for example, filing of proper accounts on time) Yes. No. Are you/will you become a member of the Association of Medical Research (AMRC) Yes. No. How much you have spent on biomedical research in the UK in the last three years (% of overallincome/wealth)
BIA | LIFE SCIENCES 2030 SKILLS STRATEGY The UK BioIndustry Association (BIA) has welcomed today’s publication of the Life Sciences 2030 Skills Strategy . The report is a key deliverable from the Life Sciences Sector Deal 2 and sets out how the UK Life Sciences sector will attract, retain, train and develop the research, manufacturing and technical skills required by a dynamic and diverse UK sector. BIA | RARE DISEASE INDUSTRY GROUP The BIA Rare Disease Industry Group (RDIG) represents a group of innovative bioscience companies that specialise in treatments for rare and ultra-rare diseases. The RDIG is committed to developing recommendations that can pragmatically inform and improve the challenge of ensuring patient access to treatments for rare and ultra-rare conditions BIA | AUSPHERIX LIMITED Auspherix Limited. Auspherix is an early-stage anti-infectives company offering new hope in the battle against antibiotic resistant bacteria. By developing a new class of antibiotics the Company will strengthen the existing arsenal of antibacterial treatments. Auspherix’ pre-clinical R&D programmes are based on its discovery ofantibacterials
GUIDANCE: FREQUENTLY ASKED QUESTIONS Page 3 of 24 8. Section 15 of the CAP conversion guidance clarifies some of the requirements for the UK MAH following the UK’s exit from the EU.However, the requirements to submit texts orBIA | GLYCOVUE LTD
GlycoVue Ltd. GlycoVue is a spin-off from the University of Cambridge and represents the accumulation of more than 15 years of experimental research in near-continuous glucose monitoring in readily accessible biological fluids. GlycoVue combines glucose-responsive smart polymers with advanced holography and AI-enabled smartphone-based BIA | CELL MEDICA LTD Cell Medica Ltd. Cell Medica is developing transformative new treatments for cancer based genetically engineering the patient’s immune cells to recognize and kill and malignant cells. Our strategy targets solid tumors and includes both autologous and allogeneic (off-the-shelf) cell therapies incorporating chimeric antigen receptors (CARs) and CELL AND GENE THERAPY EXPLAINED A GUIDE TO CELL AND GENE CAR-T cell-based medicines include both a gene therapy element (the new receptor molecule) and a cell therapy element (the cells injected back into the patient). VACCINE MANUFACTURING TASKFORCE KEY MESSAGES Influence, connect, save www.bioindustry.org 1,000,000 from 200L of cell culture, which is not uncommon. The ambition is a realistic oneand
BIA | GARDEN PARTY 2021 #BIAGardenParty. Since we will be able to meet in person again from the summer, we have decided to throw a garden party! This will give the community the chance to finally meet face to face and make up for the missed networking opportunities that our traditional January Galadinner offers.
BIA | CHARITY OF THE YEAR 2022 APPLICATION FORM Yes. No. Are you properly constituted and compliant with all areas of charity law (for example, filing of proper accounts on time) Yes. No. Are you/will you become a member of the Association of Medical Research (AMRC) Yes. No. How much you have spent on biomedical research in the UK in the last three years (% of overallincome/wealth)
BIA | LIFE SCIENCES 2030 SKILLS STRATEGY The UK BioIndustry Association (BIA) has welcomed today’s publication of the Life Sciences 2030 Skills Strategy . The report is a key deliverable from the Life Sciences Sector Deal 2 and sets out how the UK Life Sciences sector will attract, retain, train and develop the research, manufacturing and technical skills required by a dynamic and diverse UK sector. BIA | RARE DISEASE INDUSTRY GROUP The BIA Rare Disease Industry Group (RDIG) represents a group of innovative bioscience companies that specialise in treatments for rare and ultra-rare diseases. The RDIG is committed to developing recommendations that can pragmatically inform and improve the challenge of ensuring patient access to treatments for rare and ultra-rare conditions BIA | AUSPHERIX LIMITED Auspherix Limited. Auspherix is an early-stage anti-infectives company offering new hope in the battle against antibiotic resistant bacteria. By developing a new class of antibiotics the Company will strengthen the existing arsenal of antibacterial treatments. Auspherix’ pre-clinical R&D programmes are based on its discovery ofantibacterials
GUIDANCE: FREQUENTLY ASKED QUESTIONS Page 3 of 24 8. Section 15 of the CAP conversion guidance clarifies some of the requirements for the UK MAH following the UK’s exit from the EU.However, the requirements to submit texts orBIA | GLYCOVUE LTD
GlycoVue Ltd. GlycoVue is a spin-off from the University of Cambridge and represents the accumulation of more than 15 years of experimental research in near-continuous glucose monitoring in readily accessible biological fluids. GlycoVue combines glucose-responsive smart polymers with advanced holography and AI-enabled smartphone-based BIA | CELL MEDICA LTD Cell Medica Ltd. Cell Medica is developing transformative new treatments for cancer based genetically engineering the patient’s immune cells to recognize and kill and malignant cells. Our strategy targets solid tumors and includes both autologous and allogeneic (off-the-shelf) cell therapies incorporating chimeric antigen receptors (CARs) and CELL AND GENE THERAPY EXPLAINED A GUIDE TO CELL AND GENE CAR-T cell-based medicines include both a gene therapy element (the new receptor molecule) and a cell therapy element (the cells injected back into the patient). VACCINE MANUFACTURING TASKFORCE KEY MESSAGES Influence, connect, save www.bioindustry.org 1,000,000 from 200L of cell culture, which is not uncommon. The ambition is a realistic oneand
BIA | BIA START-UP FESTIVAL The BIA are delighted to announce a new event for emerging companies, the BIA Start-up Festival, which will take place in virtual format this May. This event will bring together the best of rising talent in the sector for a day of networking, 1-1 meetings, and educational sessions designed to build on your existing knowledge and allow you to BIA | MMIP VIRTUAL CONFERENCE We’re delighted to announce the annual MMIP conference, to be held virtually on Wednesday 16 June, 13.00 to 17.00. The pandemic has highlighted the importance of global medicines supply chains, and generated unprecedented discussion around the manufacturing of medicines and vaccines; there has even been public discussion in the media about the challenges of manufacturing scale up and batch BIA | CHARITY OF THE YEAR 2022 APPLICATION FORM Yes. No. Are you properly constituted and compliant with all areas of charity law (for example, filing of proper accounts on time) Yes. No. Are you/will you become a member of the Association of Medical Research (AMRC) Yes. No. How much you have spent on biomedical research in the UK in the last three years (% of overallincome/wealth)
BIA | LIFE SCIENCES 2030 SKILLS STRATEGY The UK BioIndustry Association (BIA) has welcomed today’s publication of the Life Sciences 2030 Skills Strategy . The report is a key deliverable from the Life Sciences Sector Deal 2 and sets out how the UK Life Sciences sector will attract, retain, train and develop the research, manufacturing and technical skills required by a dynamic and diverse UK sector. BIA | VISUSNANO OPENS NEW FACILITY AT DISCOVERY PARK AND Sandwich, Kent, 17th September 2020 Medtech company VisusNano announces the opening of its 800 sq. ft facility at Discovery Park, the Life Sciences Opportunity Zone for ambitious and growingcompanies.
BIA | IKSUDA THERAPEUTICS CLOSES $47 MILLION FINANCING ROUND Newcastle, UK, 7 June 2021: Iksuda Therapeutics (Iksuda), the developer of a new generation of antibody drug conjugates (ADCs) with raised therapeutic index, today announced it has completed a US $47 million (circa GB £34 million) financing round, co-led by Mirae Asset Capital and its subsidiaries, Celltrion and Premier Partners, with the Company being advised by Ashfords LLP. BIA | GENOMICS ADVISORY COMMITTEE (GAC) The BIA’s Genomics Advisory Committee (GAC) ensures that the UK starts, scales and builds world leading genomic businesses. The Committee acts as a leadership platform for sharing and discussing issues of common concern between genomic businesses and provides expert advice to the BIA to collectively input to relevant policy discussions, especially with the UK government. BIA | ARECOR APPOINTS DR. LINDSEY FOULKES AS CHIEF Arecor Therapeutics plc (“Arecor”, the “Company” or the “Group”) ARECOR APPOINTS DR. LINDSEY FOULKES AS CHIEF OPERATING OFFICER Cambridge, UK, 10 June 2021: Arecor Therapeutics plc (AIM: AREC), a globally focused biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces the appointment of Dr. Lindsey Foulkes as the Company’s Chief BIA | WHP COMPLETES THE MANUFACTURE OF THEIR LARGEST Multi-disciplinary engineering company WHP were awarded the contract to design and build a fully modularised containment facility. The project comprised the design and manufacture of 122 cGMP modules, making it one of the largest modular cGMP facilities in Europe. BIA | WHP COMPLETES NEW CLEANROOM AND PRODUCTION New state of the art cleanroom and production facilities for a leading UK MHRA approved and NHS Accredited Specials Manufacturing Company will assist them in their goal of becoming a centre of medical cannabis excellence for the UK. BIA | HOMEPAGEMEMBERSEVENTSNEWSPOLICYABOUT USJOIN OR LOGIN BIA biotech manifesto 2019. The United Kingdom (UK) will have a general election on Thursday, 12 December. The UK BioIndustry Association (BIA) has launched a biotech manifesto with its recommendations on how political parties can support the innovative UK life sciences sector. BIA | GARDEN PARTY 2021 #BIAGardenParty. Since we will be able to meet in person again from the summer, we have decided to throw a garden party! This will give the community the chance to finally meet face to face and make up for the missed networking opportunities that our traditional January Galadinner offers.
BIA | CHARITY PARTNERSHIP OF THE YEAR The BioIndustry Association (BIA) is proud to be working with Ovarian Cancer Action as its charity partner for 2021. One woman dies in the UK from ovarian cancer every two hours and although five-year survival rates for ovarian cancer are improving, other cancers, such as breast cancer, had better survival rates two generations ago than ovariancancer does today.
BIA | BIA START-UP FESTIVAL The BIA are delighted to announce a new event for emerging companies, the BIA Start-up Festival, which will take place in virtual format this May. This event will bring together the best of rising talent in the sector for a day of networking, 1-1 meetings, and educational sessions designed to build on your existing knowledge and allow you to BIA | UK-EU TRADE AND COOPERATION AGREEMENT 18 Jan 21. BIA Blog. The UK and EU negotiators reached agreement on the future relationship just days before the end of the Brexit transition period, ending UK’s participation in the EU’s Single Market and Customs Union. The UK-EU Trade and Cooperation Agreement concluded on 24 December 2020, was ratified by the UK Parliament on 30December
BIA | RARE DISEASE INDUSTRY GROUP The BIA Rare Disease Industry Group (RDIG) represents a group of innovative bioscience companies that specialise in treatments for rare and ultra-rare diseases. The RDIG is committed to developing recommendations that can pragmatically inform and improve the challenge of ensuring patient access to treatments for rare and ultra-rare conditions BIA | WOMEN IN BIOTECH Wednesday 4 March 2020. This March our Women in Biotech series returns to London, scheduled for the same week as International Women’s Day 2020. Join us for an excellent evening of networking, drinks, and thought-provoking discussion. The BIA are delighted to welcome speakers from an exciting new project at our Women in Biotech eventthis March.
BIA | GLYCOVUE LTD
GlycoVue Ltd. GlycoVue is a spin-off from the University of Cambridge and represents the accumulation of more than 15 years of experimental research in near-continuous glucose monitoring in readily accessible biological fluids. GlycoVue combines glucose-responsive smart polymers with advanced holography and AI-enabled smartphone-based GUIDANCE: FREQUENTLY ASKED QUESTIONS Page 3 of 24 8. Section 15 of the CAP conversion guidance clarifies some of the requirements for the UK MAH following the UK’s exit from the EU.However, the requirements to submit texts or CELL AND GENE THERAPY EXPLAINED A GUIDE TO CELL AND GENE CAR-T cell-based medicines include both a gene therapy element (the new receptor molecule) and a cell therapy element (the cells injected back into the patient). BIA | HOMEPAGEMEMBERSEVENTSNEWSPOLICYABOUT USJOIN OR LOGIN BIA biotech manifesto 2019. The United Kingdom (UK) will have a general election on Thursday, 12 December. The UK BioIndustry Association (BIA) has launched a biotech manifesto with its recommendations on how political parties can support the innovative UK life sciences sector. BIA | GARDEN PARTY 2021 #BIAGardenParty. Since we will be able to meet in person again from the summer, we have decided to throw a garden party! This will give the community the chance to finally meet face to face and make up for the missed networking opportunities that our traditional January Galadinner offers.
BIA | CHARITY PARTNERSHIP OF THE YEAR The BioIndustry Association (BIA) is proud to be working with Ovarian Cancer Action as its charity partner for 2021. One woman dies in the UK from ovarian cancer every two hours and although five-year survival rates for ovarian cancer are improving, other cancers, such as breast cancer, had better survival rates two generations ago than ovariancancer does today.
BIA | BIA START-UP FESTIVAL The BIA are delighted to announce a new event for emerging companies, the BIA Start-up Festival, which will take place in virtual format this May. This event will bring together the best of rising talent in the sector for a day of networking, 1-1 meetings, and educational sessions designed to build on your existing knowledge and allow you to BIA | UK-EU TRADE AND COOPERATION AGREEMENT 18 Jan 21. BIA Blog. The UK and EU negotiators reached agreement on the future relationship just days before the end of the Brexit transition period, ending UK’s participation in the EU’s Single Market and Customs Union. The UK-EU Trade and Cooperation Agreement concluded on 24 December 2020, was ratified by the UK Parliament on 30December
BIA | RARE DISEASE INDUSTRY GROUP The BIA Rare Disease Industry Group (RDIG) represents a group of innovative bioscience companies that specialise in treatments for rare and ultra-rare diseases. The RDIG is committed to developing recommendations that can pragmatically inform and improve the challenge of ensuring patient access to treatments for rare and ultra-rare conditions BIA | WOMEN IN BIOTECH Wednesday 4 March 2020. This March our Women in Biotech series returns to London, scheduled for the same week as International Women’s Day 2020. Join us for an excellent evening of networking, drinks, and thought-provoking discussion. The BIA are delighted to welcome speakers from an exciting new project at our Women in Biotech eventthis March.
GUIDANCE: FREQUENTLY ASKED QUESTIONS Page 3 of 24 8. Section 15 of the CAP conversion guidance clarifies some of the requirements for the UK MAH following the UK’s exit from the EU.However, the requirements to submit texts orBIA | GLYCOVUE LTD
GlycoVue Ltd. GlycoVue is a spin-off from the University of Cambridge and represents the accumulation of more than 15 years of experimental research in near-continuous glucose monitoring in readily accessible biological fluids. GlycoVue combines glucose-responsive smart polymers with advanced holography and AI-enabled smartphone-based CELL AND GENE THERAPY EXPLAINED A GUIDE TO CELL AND GENE CAR-T cell-based medicines include both a gene therapy element (the new receptor molecule) and a cell therapy element (the cells injected back into the patient). BIA | CHARITY PARTNERSHIP OF THE YEAR The BioIndustry Association (BIA) is proud to be working with Ovarian Cancer Action as its charity partner for 2021. One woman dies in the UK from ovarian cancer every two hours and although five-year survival rates for ovarian cancer are improving, other cancers, such as breast cancer, had better survival rates two generations ago than ovariancancer does today.
BIA | MMIP VIRTUAL CONFERENCE We’re delighted to announce the annual MMIP conference, to be held virtually on Wednesday 16 June, 13.00 to 17.00. The pandemic has highlighted the importance of global medicines supply chains, and generated unprecedented discussion around the manufacturing of medicines and vaccines; there has even been public discussion in the media about the challenges of manufacturing scale up and batch BIA | GUEST BLOG | GOVERNMENT COMMITS TO LOOKING DEEPER AT On 23 March 2021, the UK Government published its response to its call for views on artificial intelligence and intellectual property.This was an important consultation looking at a range of issues, but most significantly for the life sciences sector, it asked if inventions derived from artificial intelligence (AI) machines should be afforded the same protections as human inventions. BIA | DIVERSITY IN BIOTECH Heather is a post graduate who has worked as an HR practitioner for over 25 years in industries ranging from North Sea Oil, through Technology, Space and Imaging before landing in Pharma and Biotech with key roles in Roche/Genentech and GSK, over eight years, as a global HR business partner, supporting leadership teams in Research and Development divisions. BIA | WHP COMPLETES THE MANUFACTURE OF THEIR LARGEST Multi-disciplinary engineering company WHP were awarded the contract to design and build a fully modularised containment facility. The project comprised the design and manufacture of 122 cGMP modules, making it one of the largest modular cGMP facilities in Europe. BIA | IKSUDA THERAPEUTICS CLOSES $47 MILLION FINANCING ROUND Newcastle, UK, 7 June 2021: Iksuda Therapeutics (Iksuda), the developer of a new generation of antibody drug conjugates (ADCs) with raised therapeutic index, today announced it has completed a US $47 million (circa GB £34 million) financing round, co-led by Mirae Asset Capital and its subsidiaries, Celltrion and Premier Partners, with the Company being advised by Ashfords LLP. BIA | WHP COMPLETES NEW CLEANROOM AND PRODUCTION New state of the art cleanroom and production facilities for a leading UK MHRA approved and NHS Accredited Specials Manufacturing Company will assist them in their goal of becoming a centre of medical cannabis excellence for the UK. BIA | LEADING INNOVATION|THE UK'S ATMP LANDSCAPE The report shows that: Financings for ATMP companies grew 66% from 473m to £785m between 2017 and 2018 and stand at £347m for 2019 year to date. More than 70 ATMP developers are active in the UK, including 56 headquartered in the country. Ninety-three ATMP clinical trials are ongoing in the UK, including 27 sponsored by UK companie. BIA | ARECOR APPOINTS DR. LINDSEY FOULKES AS CHIEF Arecor Therapeutics plc (“Arecor”, the “Company” or the “Group”) ARECOR APPOINTS DR. LINDSEY FOULKES AS CHIEF OPERATING OFFICER Cambridge, UK, 10 June 2021: Arecor Therapeutics plc (AIM: AREC), a globally focused biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces the appointment of Dr. Lindsey Foulkes as the Company’s Chief BIA | CELL MEDICA LTD Cell Medica Ltd. Cell Medica is developing transformative new treatments for cancer based genetically engineering the patient’s immune cells to recognize and kill and malignant cells. Our strategy targets solid tumors and includes both autologous and allogeneic (off-the-shelf) cell therapies incorporating chimeric antigen receptors (CARs) and BIA | HOMEPAGEMEMBERSEVENTSNEWSPOLICYABOUT USJOIN OR LOGIN BIA biotech manifesto 2019. The United Kingdom (UK) will have a general election on Thursday, 12 December. The UK BioIndustry Association (BIA) has launched a biotech manifesto with its recommendations on how political parties can support the innovative UK life sciences sector. BIA | GARDEN PARTY 2021 #BIAGardenParty. Since we will be able to meet in person again from the summer, we have decided to throw a garden party! This will give the community the chance to finally meet face to face and make up for the missed networking opportunities that our traditional January Galadinner offers.
BIA | CHARITY PARTNERSHIP OF THE YEAR The BioIndustry Association (BIA) is proud to be working with Ovarian Cancer Action as its charity partner for 2021. One woman dies in the UK from ovarian cancer every two hours and although five-year survival rates for ovarian cancer are improving, other cancers, such as breast cancer, had better survival rates two generations ago than ovariancancer does today.
BIA | BIA START-UP FESTIVAL The BIA are delighted to announce a new event for emerging companies, the BIA Start-up Festival, which will take place in virtual format this May. This event will bring together the best of rising talent in the sector for a day of networking, 1-1 meetings, and educational sessions designed to build on your existing knowledge and allow you to BIA | UK-EU TRADE AND COOPERATION AGREEMENT 18 Jan 21. BIA Blog. The UK and EU negotiators reached agreement on the future relationship just days before the end of the Brexit transition period, ending UK’s participation in the EU’s Single Market and Customs Union. The UK-EU Trade and Cooperation Agreement concluded on 24 December 2020, was ratified by the UK Parliament on 30December
BIA | RARE DISEASE INDUSTRY GROUP The BIA Rare Disease Industry Group (RDIG) represents a group of innovative bioscience companies that specialise in treatments for rare and ultra-rare diseases. The RDIG is committed to developing recommendations that can pragmatically inform and improve the challenge of ensuring patient access to treatments for rare and ultra-rare conditions BIA | WOMEN IN BIOTECH Wednesday 4 March 2020. This March our Women in Biotech series returns to London, scheduled for the same week as International Women’s Day 2020. Join us for an excellent evening of networking, drinks, and thought-provoking discussion. The BIA are delighted to welcome speakers from an exciting new project at our Women in Biotech eventthis March.
BIA | GLYCOVUE LTD
GlycoVue Ltd. GlycoVue is a spin-off from the University of Cambridge and represents the accumulation of more than 15 years of experimental research in near-continuous glucose monitoring in readily accessible biological fluids. GlycoVue combines glucose-responsive smart polymers with advanced holography and AI-enabled smartphone-based GUIDANCE: FREQUENTLY ASKED QUESTIONS Page 3 of 24 8. Section 15 of the CAP conversion guidance clarifies some of the requirements for the UK MAH following the UK’s exit from the EU.However, the requirements to submit texts or CELL AND GENE THERAPY EXPLAINED A GUIDE TO CELL AND GENE CAR-T cell-based medicines include both a gene therapy element (the new receptor molecule) and a cell therapy element (the cells injected back into the patient). BIA | HOMEPAGEMEMBERSEVENTSNEWSPOLICYABOUT USJOIN OR LOGIN BIA biotech manifesto 2019. The United Kingdom (UK) will have a general election on Thursday, 12 December. The UK BioIndustry Association (BIA) has launched a biotech manifesto with its recommendations on how political parties can support the innovative UK life sciences sector. BIA | GARDEN PARTY 2021 #BIAGardenParty. Since we will be able to meet in person again from the summer, we have decided to throw a garden party! This will give the community the chance to finally meet face to face and make up for the missed networking opportunities that our traditional January Galadinner offers.
BIA | CHARITY PARTNERSHIP OF THE YEAR The BioIndustry Association (BIA) is proud to be working with Ovarian Cancer Action as its charity partner for 2021. One woman dies in the UK from ovarian cancer every two hours and although five-year survival rates for ovarian cancer are improving, other cancers, such as breast cancer, had better survival rates two generations ago than ovariancancer does today.
BIA | BIA START-UP FESTIVAL The BIA are delighted to announce a new event for emerging companies, the BIA Start-up Festival, which will take place in virtual format this May. This event will bring together the best of rising talent in the sector for a day of networking, 1-1 meetings, and educational sessions designed to build on your existing knowledge and allow you to BIA | UK-EU TRADE AND COOPERATION AGREEMENT 18 Jan 21. BIA Blog. The UK and EU negotiators reached agreement on the future relationship just days before the end of the Brexit transition period, ending UK’s participation in the EU’s Single Market and Customs Union. The UK-EU Trade and Cooperation Agreement concluded on 24 December 2020, was ratified by the UK Parliament on 30December
BIA | RARE DISEASE INDUSTRY GROUP The BIA Rare Disease Industry Group (RDIG) represents a group of innovative bioscience companies that specialise in treatments for rare and ultra-rare diseases. The RDIG is committed to developing recommendations that can pragmatically inform and improve the challenge of ensuring patient access to treatments for rare and ultra-rare conditions BIA | WOMEN IN BIOTECH Wednesday 4 March 2020. This March our Women in Biotech series returns to London, scheduled for the same week as International Women’s Day 2020. Join us for an excellent evening of networking, drinks, and thought-provoking discussion. The BIA are delighted to welcome speakers from an exciting new project at our Women in Biotech eventthis March.
BIA | GLYCOVUE LTD
GlycoVue Ltd. GlycoVue is a spin-off from the University of Cambridge and represents the accumulation of more than 15 years of experimental research in near-continuous glucose monitoring in readily accessible biological fluids. GlycoVue combines glucose-responsive smart polymers with advanced holography and AI-enabled smartphone-based GUIDANCE: FREQUENTLY ASKED QUESTIONS Page 3 of 24 8. Section 15 of the CAP conversion guidance clarifies some of the requirements for the UK MAH following the UK’s exit from the EU.However, the requirements to submit texts or CELL AND GENE THERAPY EXPLAINED A GUIDE TO CELL AND GENE CAR-T cell-based medicines include both a gene therapy element (the new receptor molecule) and a cell therapy element (the cells injected back into the patient). BIA | CHARITY PARTNERSHIP OF THE YEAR The BioIndustry Association (BIA) is proud to be working with Ovarian Cancer Action as its charity partner for 2021. One woman dies in the UK from ovarian cancer every two hours and although five-year survival rates for ovarian cancer are improving, other cancers, such as breast cancer, had better survival rates two generations ago than ovariancancer does today.
BIA | MMIP VIRTUAL CONFERENCE We’re delighted to announce the annual MMIP conference, to be held virtually on Wednesday 16 June, 13.00 to 17.00. The pandemic has highlighted the importance of global medicines supply chains, and generated unprecedented discussion around the manufacturing of medicines and vaccines; there has even been public discussion in the media about the challenges of manufacturing scale up and batch BIA | ARECOR APPOINTS DR. LINDSEY FOULKES AS CHIEF Arecor Therapeutics plc (“Arecor”, the “Company” or the “Group”) ARECOR APPOINTS DR. LINDSEY FOULKES AS CHIEF OPERATING OFFICER Cambridge, UK, 10 June 2021: Arecor Therapeutics plc (AIM: AREC), a globally focused biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces the appointment of Dr. Lindsey Foulkes as the Company’s Chief BIA | GUEST BLOG | GOVERNMENT COMMITS TO LOOKING DEEPER AT On 23 March 2021, the UK Government published its response to its call for views on artificial intelligence and intellectual property.This was an important consultation looking at a range of issues, but most significantly for the life sciences sector, it asked if inventions derived from artificial intelligence (AI) machines should be afforded the same protections as human inventions. BIA | NATIONAL SECURITY AND INVESTMENT REGIME OVERVIEW The National Security and Investment (NSI) regime is the UK Government’s new approach to scrutinising and intervening in business transactions, both foreign and domestic, where necessary to protect national security. It gives the Government the powers to screen investments and carry out national security assessments of certain transactions BIA | LEADING INNOVATION|THE UK'S ATMP LANDSCAPE The report shows that: Financings for ATMP companies grew 66% from 473m to £785m between 2017 and 2018 and stand at £347m for 2019 year to date. More than 70 ATMP developers are active in the UK, including 56 headquartered in the country. Ninety-three ATMP clinical trials are ongoing in the UK, including 27 sponsored by UK companie. BIA | DIVERSITY IN BIOTECH Heather is a post graduate who has worked as an HR practitioner for over 25 years in industries ranging from North Sea Oil, through Technology, Space and Imaging before landing in Pharma and Biotech with key roles in Roche/Genentech and GSK, over eight years, as a global HR business partner, supporting leadership teams in Research and Development divisions. BIA | BIA WELCOMES £1BN INVESTMENT DEAL AND LAUNCH OF LIFE BIA welcomes £1bn investment deal and launch of Life Sciences Investment Programme. 24 Mar 21. Press Release. Steve Bates OBE, Chief Executive of the BioIndustry Association said: “Congratulations to the Government’s new Office for Investment for securing the £1 billion UAE-UK Sovereign Investment Partnership, which I am delightedto see
BIA | CELL MEDICA LTD Cell Medica Ltd. Cell Medica is developing transformative new treatments for cancer based genetically engineering the patient’s immune cells to recognize and kill and malignant cells. Our strategy targets solid tumors and includes both autologous and allogeneic (off-the-shelf) cell therapies incorporating chimeric antigen receptors (CARs) and BIA REGIONAL FOCUS: ADVANCED THERAPIES IN THE SOUTH WEST The BIA is delighted to announce a South West regional event, this year taking place in virtual format, which will focus on advanced therapies in the South West of the UK. There have been lots of exciting developments and success stories from the region in recent months, across the full developmental pathway, from developing veryearly stage
BIA | HOMEPAGEMEMBERSEVENTSNEWSPOLICYABOUT USJOIN OR LOGIN BIA biotech manifesto 2019. The United Kingdom (UK) will have a general election on Thursday, 12 December. The UK BioIndustry Association (BIA) has launched a biotech manifesto with its recommendations on how political parties can support the innovative UK life sciences sector. BIA | GARDEN PARTY 2021 #BIAGardenParty. Since we will be able to meet in person again from the summer, we have decided to throw a garden party! This will give the community the chance to finally meet face to face and make up for the missed networking opportunities that our traditional January Galadinner offers.
BIA | CHARITY PARTNERSHIP OF THE YEAR The BioIndustry Association (BIA) is proud to be working with Ovarian Cancer Action as its charity partner for 2021. One woman dies in the UK from ovarian cancer every two hours and although five-year survival rates for ovarian cancer are improving, other cancers, such as breast cancer, had better survival rates two generations ago than ovariancancer does today.
BIA | BIA START-UP FESTIVAL The BIA are delighted to announce a new event for emerging companies, the BIA Start-up Festival, which will take place in virtual format this May. This event will bring together the best of rising talent in the sector for a day of networking, 1-1 meetings, and educational sessions designed to build on your existing knowledge and allow you to BIA | UK-EU TRADE AND COOPERATION AGREEMENT 18 Jan 21. BIA Blog. The UK and EU negotiators reached agreement on the future relationship just days before the end of the Brexit transition period, ending UK’s participation in the EU’s Single Market and Customs Union. The UK-EU Trade and Cooperation Agreement concluded on 24 December 2020, was ratified by the UK Parliament on 30December
BIA | RARE DISEASE INDUSTRY GROUP The BIA Rare Disease Industry Group (RDIG) represents a group of innovative bioscience companies that specialise in treatments for rare and ultra-rare diseases. The RDIG is committed to developing recommendations that can pragmatically inform and improve the challenge of ensuring patient access to treatments for rare and ultra-rare conditions BIA | WOMEN IN BIOTECH Wednesday 4 March 2020. This March our Women in Biotech series returns to London, scheduled for the same week as International Women’s Day 2020. Join us for an excellent evening of networking, drinks, and thought-provoking discussion. The BIA are delighted to welcome speakers from an exciting new project at our Women in Biotech eventthis March.
BIA | GLYCOVUE LTD
GlycoVue Ltd. GlycoVue is a spin-off from the University of Cambridge and represents the accumulation of more than 15 years of experimental research in near-continuous glucose monitoring in readily accessible biological fluids. GlycoVue combines glucose-responsive smart polymers with advanced holography and AI-enabled smartphone-based GUIDANCE: FREQUENTLY ASKED QUESTIONS Page 3 of 24 8. Section 15 of the CAP conversion guidance clarifies some of the requirements for the UK MAH following the UK’s exit from the EU.However, the requirements to submit texts or CELL AND GENE THERAPY EXPLAINED A GUIDE TO CELL AND GENE CAR-T cell-based medicines include both a gene therapy element (the new receptor molecule) and a cell therapy element (the cells injected back into the patient). BIA | HOMEPAGEMEMBERSEVENTSNEWSPOLICYABOUT USJOIN OR LOGIN BIA biotech manifesto 2019. The United Kingdom (UK) will have a general election on Thursday, 12 December. The UK BioIndustry Association (BIA) has launched a biotech manifesto with its recommendations on how political parties can support the innovative UK life sciences sector. BIA | GARDEN PARTY 2021 #BIAGardenParty. Since we will be able to meet in person again from the summer, we have decided to throw a garden party! This will give the community the chance to finally meet face to face and make up for the missed networking opportunities that our traditional January Galadinner offers.
BIA | CHARITY PARTNERSHIP OF THE YEAR The BioIndustry Association (BIA) is proud to be working with Ovarian Cancer Action as its charity partner for 2021. One woman dies in the UK from ovarian cancer every two hours and although five-year survival rates for ovarian cancer are improving, other cancers, such as breast cancer, had better survival rates two generations ago than ovariancancer does today.
BIA | BIA START-UP FESTIVAL The BIA are delighted to announce a new event for emerging companies, the BIA Start-up Festival, which will take place in virtual format this May. This event will bring together the best of rising talent in the sector for a day of networking, 1-1 meetings, and educational sessions designed to build on your existing knowledge and allow you to BIA | UK-EU TRADE AND COOPERATION AGREEMENT 18 Jan 21. BIA Blog. The UK and EU negotiators reached agreement on the future relationship just days before the end of the Brexit transition period, ending UK’s participation in the EU’s Single Market and Customs Union. The UK-EU Trade and Cooperation Agreement concluded on 24 December 2020, was ratified by the UK Parliament on 30December
BIA | RARE DISEASE INDUSTRY GROUP The BIA Rare Disease Industry Group (RDIG) represents a group of innovative bioscience companies that specialise in treatments for rare and ultra-rare diseases. The RDIG is committed to developing recommendations that can pragmatically inform and improve the challenge of ensuring patient access to treatments for rare and ultra-rare conditions BIA | WOMEN IN BIOTECH Wednesday 4 March 2020. This March our Women in Biotech series returns to London, scheduled for the same week as International Women’s Day 2020. Join us for an excellent evening of networking, drinks, and thought-provoking discussion. The BIA are delighted to welcome speakers from an exciting new project at our Women in Biotech eventthis March.
BIA | GLYCOVUE LTD
GlycoVue Ltd. GlycoVue is a spin-off from the University of Cambridge and represents the accumulation of more than 15 years of experimental research in near-continuous glucose monitoring in readily accessible biological fluids. GlycoVue combines glucose-responsive smart polymers with advanced holography and AI-enabled smartphone-based GUIDANCE: FREQUENTLY ASKED QUESTIONS Page 3 of 24 8. Section 15 of the CAP conversion guidance clarifies some of the requirements for the UK MAH following the UK’s exit from the EU.However, the requirements to submit texts or CELL AND GENE THERAPY EXPLAINED A GUIDE TO CELL AND GENE CAR-T cell-based medicines include both a gene therapy element (the new receptor molecule) and a cell therapy element (the cells injected back into the patient). BIA | CHARITY PARTNERSHIP OF THE YEAR The BioIndustry Association (BIA) is proud to be working with Ovarian Cancer Action as its charity partner for 2021. One woman dies in the UK from ovarian cancer every two hours and although five-year survival rates for ovarian cancer are improving, other cancers, such as breast cancer, had better survival rates two generations ago than ovariancancer does today.
BIA | MMIP VIRTUAL CONFERENCE We’re delighted to announce the annual MMIP conference, to be held virtually on Wednesday 16 June, 13.00 to 17.00. The pandemic has highlighted the importance of global medicines supply chains, and generated unprecedented discussion around the manufacturing of medicines and vaccines; there has even been public discussion in the media about the challenges of manufacturing scale up and batch BIA | ARECOR APPOINTS DR. LINDSEY FOULKES AS CHIEF Arecor Therapeutics plc (“Arecor”, the “Company” or the “Group”) ARECOR APPOINTS DR. LINDSEY FOULKES AS CHIEF OPERATING OFFICER Cambridge, UK, 10 June 2021: Arecor Therapeutics plc (AIM: AREC), a globally focused biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces the appointment of Dr. Lindsey Foulkes as the Company’s Chief BIA | GUEST BLOG | GOVERNMENT COMMITS TO LOOKING DEEPER AT On 23 March 2021, the UK Government published its response to its call for views on artificial intelligence and intellectual property.This was an important consultation looking at a range of issues, but most significantly for the life sciences sector, it asked if inventions derived from artificial intelligence (AI) machines should be afforded the same protections as human inventions. BIA | NATIONAL SECURITY AND INVESTMENT REGIME OVERVIEW The National Security and Investment (NSI) regime is the UK Government’s new approach to scrutinising and intervening in business transactions, both foreign and domestic, where necessary to protect national security. It gives the Government the powers to screen investments and carry out national security assessments of certain transactions BIA | LEADING INNOVATION|THE UK'S ATMP LANDSCAPE The report shows that: Financings for ATMP companies grew 66% from 473m to £785m between 2017 and 2018 and stand at £347m for 2019 year to date. More than 70 ATMP developers are active in the UK, including 56 headquartered in the country. Ninety-three ATMP clinical trials are ongoing in the UK, including 27 sponsored by UK companie. BIA | DIVERSITY IN BIOTECH Heather is a post graduate who has worked as an HR practitioner for over 25 years in industries ranging from North Sea Oil, through Technology, Space and Imaging before landing in Pharma and Biotech with key roles in Roche/Genentech and GSK, over eight years, as a global HR business partner, supporting leadership teams in Research and Development divisions. BIA | BIA WELCOMES £1BN INVESTMENT DEAL AND LAUNCH OF LIFE BIA welcomes £1bn investment deal and launch of Life Sciences Investment Programme. 24 Mar 21. Press Release. Steve Bates OBE, Chief Executive of the BioIndustry Association said: “Congratulations to the Government’s new Office for Investment for securing the £1 billion UAE-UK Sovereign Investment Partnership, which I am delightedto see
BIA | CELL MEDICA LTD Cell Medica Ltd. Cell Medica is developing transformative new treatments for cancer based genetically engineering the patient’s immune cells to recognize and kill and malignant cells. Our strategy targets solid tumors and includes both autologous and allogeneic (off-the-shelf) cell therapies incorporating chimeric antigen receptors (CARs) and BIA REGIONAL FOCUS: ADVANCED THERAPIES IN THE SOUTH WEST The BIA is delighted to announce a South West regional event, this year taking place in virtual format, which will focus on advanced therapies in the South West of the UK. There have been lots of exciting developments and success stories from the region in recent months, across the full developmental pathway, from developing veryearly stage
BIA | HOMEPAGEMEMBERSEVENTSNEWSPOLICYABOUT USJOIN OR LOGIN BIA biotech manifesto 2019. The United Kingdom (UK) will have a general election on Thursday, 12 December. The UK BioIndustry Association (BIA) has launched a biotech manifesto with its recommendations on how political parties can support the innovative UK life sciences sector. BIA | GARDEN PARTY 2021 #BIAGardenParty. Since we will be able to meet in person again from the summer, we have decided to throw a garden party! This will give the community the chance to finally meet face to face and make up for the missed networking opportunities that our traditional January Galadinner offers.
BIA | CHARITY PARTNERSHIP OF THE YEAR The BioIndustry Association (BIA) is proud to be working with Ovarian Cancer Action as its charity partner for 2021. One woman dies in the UK from ovarian cancer every two hours and although five-year survival rates for ovarian cancer are improving, other cancers, such as breast cancer, had better survival rates two generations ago than ovariancancer does today.
BIA | BIA START-UP FESTIVAL The BIA are delighted to announce a new event for emerging companies, the BIA Start-up Festival, which will take place in virtual format this May. This event will bring together the best of rising talent in the sector for a day of networking, 1-1 meetings, and educational sessions designed to build on your existing knowledge and allow you to BIA | UK-EU TRADE AND COOPERATION AGREEMENT 18 Jan 21. BIA Blog. The UK and EU negotiators reached agreement on the future relationship just days before the end of the Brexit transition period, ending UK’s participation in the EU’s Single Market and Customs Union. The UK-EU Trade and Cooperation Agreement concluded on 24 December 2020, was ratified by the UK Parliament on 30December
BIA | RARE DISEASE INDUSTRY GROUP The BIA Rare Disease Industry Group (RDIG) represents a group of innovative bioscience companies that specialise in treatments for rare and ultra-rare diseases. The RDIG is committed to developing recommendations that can pragmatically inform and improve the challenge of ensuring patient access to treatments for rare and ultra-rare conditions BIA | WOMEN IN BIOTECH Wednesday 4 March 2020. This March our Women in Biotech series returns to London, scheduled for the same week as International Women’s Day 2020. Join us for an excellent evening of networking, drinks, and thought-provoking discussion. The BIA are delighted to welcome speakers from an exciting new project at our Women in Biotech eventthis March.
BIA | GLYCOVUE LTD
GlycoVue Ltd. GlycoVue is a spin-off from the University of Cambridge and represents the accumulation of more than 15 years of experimental research in near-continuous glucose monitoring in readily accessible biological fluids. GlycoVue combines glucose-responsive smart polymers with advanced holography and AI-enabled smartphone-based GUIDANCE: FREQUENTLY ASKED QUESTIONS Page 3 of 24 8. Section 15 of the CAP conversion guidance clarifies some of the requirements for the UK MAH following the UK’s exit from the EU.However, the requirements to submit texts or CELL AND GENE THERAPY EXPLAINED A GUIDE TO CELL AND GENE CAR-T cell-based medicines include both a gene therapy element (the new receptor molecule) and a cell therapy element (the cells injected back into the patient). BIA | HOMEPAGEMEMBERSEVENTSNEWSPOLICYABOUT USJOIN OR LOGIN BIA biotech manifesto 2019. The United Kingdom (UK) will have a general election on Thursday, 12 December. The UK BioIndustry Association (BIA) has launched a biotech manifesto with its recommendations on how political parties can support the innovative UK life sciences sector. BIA | GARDEN PARTY 2021 #BIAGardenParty. Since we will be able to meet in person again from the summer, we have decided to throw a garden party! This will give the community the chance to finally meet face to face and make up for the missed networking opportunities that our traditional January Galadinner offers.
BIA | CHARITY PARTNERSHIP OF THE YEAR The BioIndustry Association (BIA) is proud to be working with Ovarian Cancer Action as its charity partner for 2021. One woman dies in the UK from ovarian cancer every two hours and although five-year survival rates for ovarian cancer are improving, other cancers, such as breast cancer, had better survival rates two generations ago than ovariancancer does today.
BIA | BIA START-UP FESTIVAL The BIA are delighted to announce a new event for emerging companies, the BIA Start-up Festival, which will take place in virtual format this May. This event will bring together the best of rising talent in the sector for a day of networking, 1-1 meetings, and educational sessions designed to build on your existing knowledge and allow you to BIA | UK-EU TRADE AND COOPERATION AGREEMENT 18 Jan 21. BIA Blog. The UK and EU negotiators reached agreement on the future relationship just days before the end of the Brexit transition period, ending UK’s participation in the EU’s Single Market and Customs Union. The UK-EU Trade and Cooperation Agreement concluded on 24 December 2020, was ratified by the UK Parliament on 30December
BIA | RARE DISEASE INDUSTRY GROUP The BIA Rare Disease Industry Group (RDIG) represents a group of innovative bioscience companies that specialise in treatments for rare and ultra-rare diseases. The RDIG is committed to developing recommendations that can pragmatically inform and improve the challenge of ensuring patient access to treatments for rare and ultra-rare conditions BIA | WOMEN IN BIOTECH Wednesday 4 March 2020. This March our Women in Biotech series returns to London, scheduled for the same week as International Women’s Day 2020. Join us for an excellent evening of networking, drinks, and thought-provoking discussion. The BIA are delighted to welcome speakers from an exciting new project at our Women in Biotech eventthis March.
BIA | GLYCOVUE LTD
GlycoVue Ltd. GlycoVue is a spin-off from the University of Cambridge and represents the accumulation of more than 15 years of experimental research in near-continuous glucose monitoring in readily accessible biological fluids. GlycoVue combines glucose-responsive smart polymers with advanced holography and AI-enabled smartphone-based GUIDANCE: FREQUENTLY ASKED QUESTIONS Page 3 of 24 8. Section 15 of the CAP conversion guidance clarifies some of the requirements for the UK MAH following the UK’s exit from the EU.However, the requirements to submit texts or CELL AND GENE THERAPY EXPLAINED A GUIDE TO CELL AND GENE CAR-T cell-based medicines include both a gene therapy element (the new receptor molecule) and a cell therapy element (the cells injected back into the patient). BIA | CHARITY PARTNERSHIP OF THE YEAR The BioIndustry Association (BIA) is proud to be working with Ovarian Cancer Action as its charity partner for 2021. One woman dies in the UK from ovarian cancer every two hours and although five-year survival rates for ovarian cancer are improving, other cancers, such as breast cancer, had better survival rates two generations ago than ovariancancer does today.
BIA | MMIP VIRTUAL CONFERENCE We’re delighted to announce the annual MMIP conference, to be held virtually on Wednesday 16 June, 13.00 to 17.00. The pandemic has highlighted the importance of global medicines supply chains, and generated unprecedented discussion around the manufacturing of medicines and vaccines; there has even been public discussion in the media about the challenges of manufacturing scale up and batch BIA | ARECOR APPOINTS DR. LINDSEY FOULKES AS CHIEF Arecor Therapeutics plc (“Arecor”, the “Company” or the “Group”) ARECOR APPOINTS DR. LINDSEY FOULKES AS CHIEF OPERATING OFFICER Cambridge, UK, 10 June 2021: Arecor Therapeutics plc (AIM: AREC), a globally focused biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces the appointment of Dr. Lindsey Foulkes as the Company’s Chief BIA | GUEST BLOG | GOVERNMENT COMMITS TO LOOKING DEEPER AT On 23 March 2021, the UK Government published its response to its call for views on artificial intelligence and intellectual property.This was an important consultation looking at a range of issues, but most significantly for the life sciences sector, it asked if inventions derived from artificial intelligence (AI) machines should be afforded the same protections as human inventions. BIA | NATIONAL SECURITY AND INVESTMENT REGIME OVERVIEW The National Security and Investment (NSI) regime is the UK Government’s new approach to scrutinising and intervening in business transactions, both foreign and domestic, where necessary to protect national security. It gives the Government the powers to screen investments and carry out national security assessments of certain transactions BIA | LEADING INNOVATION|THE UK'S ATMP LANDSCAPE The report shows that: Financings for ATMP companies grew 66% from 473m to £785m between 2017 and 2018 and stand at £347m for 2019 year to date. More than 70 ATMP developers are active in the UK, including 56 headquartered in the country. Ninety-three ATMP clinical trials are ongoing in the UK, including 27 sponsored by UK companie. BIA | DIVERSITY IN BIOTECH Heather is a post graduate who has worked as an HR practitioner for over 25 years in industries ranging from North Sea Oil, through Technology, Space and Imaging before landing in Pharma and Biotech with key roles in Roche/Genentech and GSK, over eight years, as a global HR business partner, supporting leadership teams in Research and Development divisions. BIA | BIA WELCOMES £1BN INVESTMENT DEAL AND LAUNCH OF LIFE BIA welcomes £1bn investment deal and launch of Life Sciences Investment Programme. 24 Mar 21. Press Release. Steve Bates OBE, Chief Executive of the BioIndustry Association said: “Congratulations to the Government’s new Office for Investment for securing the £1 billion UAE-UK Sovereign Investment Partnership, which I am delightedto see
BIA | CELL MEDICA LTD Cell Medica Ltd. Cell Medica is developing transformative new treatments for cancer based genetically engineering the patient’s immune cells to recognize and kill and malignant cells. Our strategy targets solid tumors and includes both autologous and allogeneic (off-the-shelf) cell therapies incorporating chimeric antigen receptors (CARs) and BIA REGIONAL FOCUS: ADVANCED THERAPIES IN THE SOUTH WEST The BIA is delighted to announce a South West regional event, this year taking place in virtual format, which will focus on advanced therapies in the South West of the UK. There have been lots of exciting developments and success stories from the region in recent months, across the full developmental pathway, from developing veryearly stage
Menu
All results
* Members
* Member Benefits
* Developing your company * Advisory Committees * Search sector jobs * Submit member jobs * Membership directory* Events
* Supporters
* Submit your sector event* News
* Press releases
* BIA blog
* Member news
* Submit member news* Document library
* Search all news
* Policy
* Leaving the EU
* Finance, tax and investment * Access to medicines * Skills, people and talent * Pre-clinical and clinical research * Medicines Regulation * IP and tech transfer* Manufacturing
* Strategic technologies* About Us
* What is biotech?
* Meet the team
* Our board
* Charity partnership of the year* BIA Vacancies
*
* JOIN or LOGIN
Back
MEMBER LOGIN
Email address
Password
Forgotten password?
| Register
REMEMBER ME
Discover the benefits of BIA membershipScroll for more
BIA ACTION & GUIDANCE ON COVID-1930 Apr 20
Press Release
BIA WELCOMES COLLABORATION BETWEEN ASTRAZENECA AND THE JENNERINSTITUTE
17 Apr 20
Press Release
BIA INDUSTRY-LED VACCINE MANUFACTURING GROUP WELCOMES FUNDING ANNOUNCEMENT OF £14M FROM UK THE UK HAS NOW LEFT THE EU. VIEW THE BIA BREXIT PORTAL FOR UPDATES11 Mar 20
Press Release
BIA RESPONDS TO BUDGET 2020prev
next
RT @VACCITECHLTD: Vaccitech CEO Bill Enright describes the extraordinary progress being made to develop a #COVID19 #VACCINEHTTPS://T.CO/L…
In his latest CEO blog, Steve Bates highlights the developments over the past week including #VACCINE funding news,… HTTPS://T.CO/2EBDAUBFRT Missed last week's #BIAWEBINAR? Catch up via our YouTube channel!👇 HTTPS://T.CO/V39ODLEWZJ HTTPS://T.CO/BTINHFJ3BN How are biotechs using #AI to tackle COVID-19? Read this special report in the @FT featuring @BENEVOLENT_AI,… HTTPS://T.CO/MALOVUOTOW RT @INNOVATEUK: More detail of potential support for existing @INNOVATEUK customers suffering COVID-19 impact now available. Manythanks fo…
RT @VACCITECHLTD: Vaccitech CEO Bill Enright describes the extraordinary progress being made to develop a #COVID19 #VACCINEHTTPS://T.CO/L…
In his latest CEO blog, Steve Bates highlights the developments over the past week including #VACCINE funding news,… HTTPS://T.CO/2EBDAUBFRT Missed last week's #BIAWEBINAR? Catch up via our YouTube channel!👇 HTTPS://T.CO/V39ODLEWZJ HTTPS://T.CO/BTINHFJ3BN How are biotechs using #AI to tackle COVID-19? Read this special report in the @FT featuring @BENEVOLENT_AI,… HTTPS://T.CO/MALOVUOTOW RT @INNOVATEUK: More detail of potential support for existing @INNOVATEUK customers suffering COVID-19 impact now available. Manythanks fo…
RT @VACCITECHLTD: Vaccitech CEO Bill Enright describes the extraordinary progress being made to develop a #COVID19 #VACCINEHTTPS://T.CO/L…
prev
next
1 of 5
LATEST NEWS FROM BIAView all news
* Press Releases
* Member News
* BIA blog
* Our publications
Press Releases
12 May 20
Press Release
BIA RESPONDS TO CASH INJECTION OF €117M TO EIGHT CORONAVIRUS PROJECTS BY THE EUROPEAN COMMISSION Commenting on today’s announcement of €117 million awarded to eight coronavirus projects by the European Commission, Steve Bates OBE, Chief Executive of the BIA said:01 May 20
Press Release
HEALTH SECRETARY PAYS TRIBUTE TO UK LIFE SCIENCES COMPANIES, AS TESTING RAMPS UP FOR COVID-19 Commenting on the day of the 100,000 testing target, Steve Bates OBE, Chief Executive of the BIA said: “It’s gratifying to see the Government recognises the major role the UK life sciences industry has played in the collaborative, speedy and innovative national effort to increase testing capability.30 Apr 20
Press Release
BIA INDUSTRY-LED VACCINE MANUFACTURING TASKFORCE WELCOMES COLLABORATION ANNOUNCEMENT BETWEEN ASTRAZENECA AND THE JENNER INSTITUTE ON DEVELOPING A COVID-19 VACCINE Steve Bates OBE, Chief Executive of the BIA said: “UK life sciences companies already working on key elements of manufacturing, through the BIA taskforce, look forward to working with AstraZeneca on the vital development and scale up of the Jenner COVID-19 vaccine.21 Apr 20
Press Release
BIA WELCOMES FURTHER FUNDING FOR BOTH IMPERIAL AND OXFORD COVID-19 CLINICAL TRIALS AND MANUFACTURING CAPABILITY Responding to the funding announcement at today’s Downing Street COVID-19 briefing by the Health Secretary Matt Hancock, for Imperial College London and Oxford University, Steve Bates OBE, Chief Executive of the BioIndustry Association (BIA) said:See More
Member News
13 May 20
Member News
DISCOVERY PARK PART OF DOMESTIC AND GLOBAL RESPONSE TO COVID-19PANDEMIC
Science Park open for business to support community’s importantactivities
12 May 20
Member News
CIRA FOUNDATION AND THE CELL AND GENE THERAPY CATAPULT SET TO LAUNCH NEW STEM CELL COLLABORATIVE RESEARCH The companies will combine their expertise to explore novel methods to characterise pluripotent stem cells for the manufacture of regenerative medicine products.06 May 20
Member News
AI-BASED PRECISION MEDICINE MINING OF UK BIOBANK FINDS 13 HUMAN COVID RISK GENES AND IDENTIFIES 59 DRUGS WITH POTENTIAL TO IMPROVE SURVIVAL IN SEVERE COVID-19 PATIENTS AND SEPSIS • 70 sepsis risk genes identified from UK Biobank, 61% of which are present specifically in severe COVID-19 patients (‘COVID risk genes’) • 13 ‘COVID risk genes’ identified as known druggable targets • 59 compounds and drugs identified with potential for accelerated drug discovery (‘repurposing’) • Study also offers potential for identifying COVID-19 high risk biomarkers06 May 20
Member News
COULTER PARTNERS PLACES CHIEF MEDICAL OFFICER FOR SANIONA Coulter Partners was very pleased to partner recently with Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, to secure the appointment of Rudolf Baumgartner, M.D., as Chief Medical Officer and Head of Clinical Development. Dr. Baumgartner brings more than 20 years of experience leading multiple pharmaceutical development programs from discovery through approval and launch, in both large and small pharmaceutical companies.See More
BIA blog
18 May 20
BIA Blog
CEO UPDATE|MONDAY 18 MAY UK vaccine taskforce builds vaccine manufacturing capability in the UK, more details on government support for life science businesses and the approval of a coronavirus antibody test, as the UK begins exitfrom lockdown
18 May 20
BIA Blog
THE NEXT LEAP FOR FUTURE LEADERS – LEAP ALUMNI ASSOCIATION KICKS-OFF Following the success of the BIA MAC Leadership Programme (LeaP), last week saw the kick-off of the LeaP Alumni Association.11 May 20
BIA Blog
CEO UPDATE|MONDAY 11 MAY The Prime Minister’s announcements; last night and this afternoon move the UK into the next phase of the pandemic response. Over the past week we have heard more detail on the test, track and trace initiative which will help in lifting restrictions, we have seen continued global collaboration to tackle the virus and have received details from the NIHR on restarting clinical trials.07 May 20
BIA Blog
GUEST BLOG|SCIENCE AT HOME: IS IT POSSIBLE FOR RESEARCHERS TO WORKREMOTELY?
Given recent events, huge swathes of us have suddenly had to start working remotely in order to help slow the spread of COVID-19 and ease the strain on healthcare systems globally. Scientific researchers play a key role in the fight against the virus as well as other important global challenges, but is it even possible to continue researchremotely?
See More
Our publications
Please find a selection of featured BIA publications below. To see our full publications library, click here.
27 Jan 20
INFLUENCING AND SHAPING OUR SECTOR | BIA UPDATE: OCTOBER 2019 -JANUARY 2020
This quarterly update gives an overview of key policy developments and the BIA’s continued engagement with policymakers, regulatory authorities and wider stakeholders on behalf of the UK life sciences sector, from October 2019 to January 2020.22 Jan 20
Research Publications GLOBAL AND GROWING - UK BIOTECH FINANCING IN 2019 New figures published today (Wednesday 22 January 2020) by the UK BioIndustry Association (BIA) and Informa Pharma Intelligence reveal that the UK biotech sector raised £1.3 billion in 2019.19 Jan 20
UK LIFE SCIENCES: CATALYSING INVESTMENT AND GROWTH This updated interim report sets out how the UK life sciences sector is driving investment and growth and makes the case for increased cost-effective public investment in the sector.11 Nov 19
Guidance document, Policy Briefing, News Report BIA BIOTECH MANIFESTO 2019 The United Kingdom (UK) will have a general election on Thursday, 12 December. The UK BioIndustry Association (BIA) has launched a biotech manifesto with its recommendations on how political parties can support the innovative UK life sciences sector. LATEST EVENTS AT BIAView all events
04 Jun
Networking
WOMEN IN BIOTECH
22 Jun
Event
LIFE SCIENCE LEADERSHIP SUMMITOnline event
08 Sep
Event
BIA NETWORKING LUNCH - STEVENAGEStevenage
OUR SUPPORTERS
The BioIndustry Association, 7th Floor, Southside, 105 Victoria Street, London, SW1E 6QT ● Tel: +44 (0)20 7630 2180* Privacy statement
2020 The BioIndustry AssociationWeb design by Pixl8
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0